These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24757074)

  • 1. Reply: To PMID 22504829.
    Curtis JR
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1271-2. PubMed ID: 24757074
    [No Abstract]   [Full Text] [Related]  

  • 2. Editor's note.
    Hannan MT
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1272. PubMed ID: 24757066
    [No Abstract]   [Full Text] [Related]  

  • 3. Who decides if research will be published, authors or sponsors? Comment on the article by Curtis et al.
    Yazici Y
    Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1270-1. PubMed ID: 24757091
    [No Abstract]   [Full Text] [Related]  

  • 4. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.
    Curtis JR; John A; Baser O
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1282-91. PubMed ID: 22504829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reply: To PMID 25371395.
    Gregersen PK; Oswald M; Curran M; Carulli J;
    Arthritis Rheumatol; 2015 May; 67(8):2277. PubMed ID: 25989099
    [No Abstract]   [Full Text] [Related]  

  • 6. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B;
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply: To PMID 22886739.
    Simard JF; Neovius M; Askling J
    Arthritis Rheum; 2013 Jun; 65(6):1671-2. PubMed ID: 23508884
    [No Abstract]   [Full Text] [Related]  

  • 8. Dr. Keystone, et al, reply.
    J Rheumatol; 2013 May; 40(5):732-3. PubMed ID: 23767071
    [No Abstract]   [Full Text] [Related]  

  • 9. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 10. [Rheumatoid arthritis: determination of the current status].
    Michel BA
    Z Rheumatol; 2001 Oct; 60(5):307-8. PubMed ID: 11759229
    [No Abstract]   [Full Text] [Related]  

  • 11. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 12. [TNF-alpha blocker in rheumatoid arthritis. Who should be treated with the new substances?].
    MMW Fortschr Med; 2000 Nov; 142(44):6. PubMed ID: 11107796
    [No Abstract]   [Full Text] [Related]  

  • 13. TNF alpha blockade in rheumatoid arthritis--time for caution or enthusiasm?
    Hamilton JD; Wilson HE; Madhok R; McInnes IB; Capell HA
    Scott Med J; 2001 Jun; 46(3):67-70. PubMed ID: 11501322
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug treatments for rheumatoid arthritis: looking backwards to move forwards.
    Miossec P
    BMJ; 2015 Mar; 350():h1192. PubMed ID: 25769296
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effectiveness and safety of the treatment with tumour necrosis factor alpha antagonists in rheumatoid arthritis patients].
    Arenere Mendoza M; Navarro Aznárez H; Rabanaque Hernández MJ; Manero Ruiz FJ
    Med Clin (Barc); 2005 Jun; 125(1):35-6. PubMed ID: 15960943
    [No Abstract]   [Full Text] [Related]  

  • 16. Access to disease modifying treatments for rheumatoid arthritis patients.
    Furst DE; Breedveld FC; Burmester GR; Crofford L; Emery P; Feldman M; Kalden JR; Kavanaugh A; Keystone E; Lipsky PE; Maini RN; Moreland L; Smolen JS; Van De Putte L; Vischer T; Weinblatt M; Weissman M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I129-30. PubMed ID: 10577989
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 18. Drivers of costly treatment strategies in rheumatoid arthritis.
    Huizinga TW; Gröndal G
    Lancet; 2016 Jul; 388(10041):213-4. PubMed ID: 27197691
    [No Abstract]   [Full Text] [Related]  

  • 19. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.